Halozyme is a therapeutically driven biopharmaceutical company developing and commercializing recombinant human enzymes to provide enhanced and innovative products that improve the practice of medicine. Halozyme focuses on providing life-saving and life-enhancing solutions to the endocrinology, oncology, dermatology, and drug delivery markets.
The foundation of our capabilities is our recombinant human hyaluronidase enzyme, rHuPH20, which temporarily degrades hyaluronan, a structural protein in the interstitial space. This temporary alteration provides an opportunistic window that allows the delivery of injectable biologics such as monoclonal antibodies, as well as small molecules and fluids. With our enzyme, many pharmaceuticals that would normally be injected intravenously (IV) can be administered subcutaneously (SC). This change in route of delivery may improve patient convenience, enhance pharmacokinetics, boost efficacy, extend the product lifecycle, and reduce cost, in addition to other beneficial attributes.
Four key internal programs comprise our current proprietary product development portfolio. The endocrinology program consists of Insulin-PH20 and Analog-PH20, which applies our PH20 enzyme to currently approved and marketed mealtime insulin products. The oncology franchise consists of PEGPH20, a new molecular entity administered intravenously that targets the external environment of tumor cells, and Chemophase, which utilizes the PH20 enzyme for local administration in bladder cancer. Our lead enzyme within dermatology, HTI-501, is a new molecular entity which degrades collagen. It may have applications in both medical and aesthetic dermatology and other potential therapeutic categories as well. Our programs aim to be best-in-class, which will help to ensure their acceptance by patients, healthcare providers and payors.
Our product development pipeline also includes three distinct partnered programs with two companies: Roche and Baxter BioScience for Enhanze technology, and Baxter Medication Delivery for HYLENEX, our FDA-approved drug. These partnered programs validate our technology and may generate clinical and commercial milestone revenue based on the achievement of pre-specified events along with sales royalties when products reach the commercial stage. We utilize the non-dilutive cash milestone payments generated from the partnered programs as a source of development funding for our proprietary pipeline projects.